PMCCPMCCPMCC

Search tips
Search criteria 

Advanced


 
Formats
Article sections
Authors
Related links
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Curr Med Chem. Author manuscript; available in PMC 2008 February 3.
Published in final edited form as:
PMCID: PMC2225483
NIHMSID: NIHMS38146
Copyright notice and Disclaimer
Role of Nitrosative Stress and Peroxynitrite in the Pathogenesis of Diabetic Complications. Emerging New Therapeutical Strategies
Pál Pacher,1* Irina G. Obrosova,2 Jon G. Mabley,3 and Csaba Szabó4,5,6
1 National Institutes of Health, NIAAA, Laboratory of Physiologic Studies, Bethesda, MD 20892-9413, USA
2 Pennington Biomedical Research Center, Louisiana State University System, 6400 Perkins Road, Baton, Rouge, LA 70808, USA
3 School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK
4 Inotek Pharmaceuticals, Beverly, MA 01915, USA
5 Department of Surgery, UMD NJ-New Jersey Medical School, Newark, New Jersey 07103, USA
6 Institute of Human Physiology and Clinical Experimental Research, Semmelweis University, Budapest, Hungary
*Address correspondence to this author at the Laboratory of Physiologic Studies, National Institutes of Health, National Institute on Alcohol Abuse and Alcoholism, 5625 Fishers Lane MSC 9413, Room 2S24 Bethesda, MD 20892, USA; Tel: 301-496-6777; Fax: 301-963-0922; E-mail: ppacher/at/lycos.com or ; pacher/at/mail.nih.gov
Small right arrow pointing to: The publisher's final edited version of this article is available at Curr Med Chem
Small right arrow pointing to: See other articles in PMC that cite the published article.
Abstract
Macro- and microvascular disease are the most common causes of morbidity and mortality in patients with diabetes mellitus. Diabetic cardiovascular dysfunction represents a problem of great clinical importance underlying the development of various severe complications including retinopathy, nephropathy, neuropathy and increase the risk of stroke, hypertension and myocardial infarction. Hyperglycemic episodes, which complicate even well-controlled cases of diabetes, are closely associated with increased oxidative and nitrosative stress, which can trigger the development of diabetic complications. Hyperglycemia stimulates the production of advanced glycosylated end products, activates protein kinase C, and enhances the polyol pathway leading to increased superoxide anion formation. Superoxide anion interacts with nitric oxide, forming the potent cytotoxin peroxynitrite, which attacks various biomolecules in the vascular endothelium, vascular smooth muscle and myocardium, leading to cardiovascular dysfunction. The pathogenetic role of nitrosative stress and peroxynitrite, and downstream mechanisms including poly(ADP-ribose) polymerase (PARP) activation, is not limited to the diabetes-induced cardiovascular dysfunction, but also contributes to the development and progression of diabetic nephropathy, retinopathy and neuropathy. Accordingly, neutralization of peroxynitrite or pharmacological inhibition of PARP is a promising new approach in the therapy and prevention of diabetic complications. This review focuses on the role of nitrosative stress and downstream mechanisms including activation of PARP in diabetic complications and on novel emerging therapeutical strategies offered by neutralization of peroxynitrite and inhibition of PARP.
Keywords: peroxynitrite, nitric oxide, superoxide, nitrotyrosine, diabetes, vascular, cardiomyopathy, nephropathy, neuropathy, retinopathy
Diabetic state is associated with increased oxidative stress, which plays an important role in the development of diabetic complications. Hyperglycemia stimulates the production of advanced glycosylated end products, activates protein kinase C, and enhances the polyol pathway leading to increased superoxide anion formation [1–3]. Superoxide anion interacts with nitric oxide, which is produced, physiologically, by constitutive sources, such as the endothelial isoform of nitric oxide synthase (eNOS). This process leads to the formation of the strong oxidant peroxynitrite, which attacks various biomolecules leading to cellular dysfunction via multiple mechanisms (Table 1) [1,2,4–47]. One of these pathways involves DNA strand breakage and activation of the nuclear enzyme poly(ADP-ribose) polymerase, which has been covered by separate overviews [6,48,49]. The present review summarizes the accumulating experimental and clinical evidence implicating the pathogenetic role of increased nitrosative stress, peroxynitrite formation in the development of diabetic complications (Table 2). Although peroxynitrite generation also plays a role in the pathogenesis of islet-cell destruction [18,30,50], this is a separate area which is not the main focus of the present review.
Table 1
Table 1
Selected Cytotoxic Processes Initiated by Peroxynitrite, with Potential Relevance to Diabetic Complications
Table 2
Table 2
Evidence Implicating Nitrosative Stress and Peroxynitrite Formation in Diabetes and Diabetic Complications
Various neurohumoral mediators and mechanical forces acting upon the innermost layer of blood vessels, the endothelium, are involved in the regulation of the vascular tone. A main pathway of vasoregulation involves the activation of the eNOS resulting in NO production [51]. Endothelium-dependent vasodilatation is frequently used as a reproducible and accessible parameter to probe endothelial function in various pathophysiological conditions. It is well established that endothelial dysfunction, in many diseases, precedes and predicts as well as predisposes for the subsequent, more severe vascular alterations. Endothelial dysfunction has been documented in various forms of diabetes, and even in pre-diabetic individuals [3,17,21,52–57]. The pathogenesis of this endothelial dysfunction involves many components including increased polyol pathway flux, altered cellular redox state, increasedformation of diacylglycerol and the subsequent activation of specific protein kinase C isoforms, and accelerated nonenzymatic formation of advanced glycation end products [58– 63]. Many of these pathways, in concert, trigger the production of oxygen- and nitrogen-derived oxidants and free radicals, such as superoxide anion and peroxynitrite, which play a significant role in the pathogenesis of diabetes-associated endothelial dysfunction [59–61,64]. The cellular sources of reactive oxygen species such as superoxide anion are multiple and include advanced glycation end products, NAD(P)H oxidases, the mitochondrial respiratory chain, xanthine oxidase, the arachidonic acid cascade (lipoxygenase and cycloxygenase), and microsomal enzymes [1,59].
Superoxide anion may quench NO, thereby reducing the efficacy of a potent endothelium-derived vasodilator system that participates in the homeostatic regulation of the vasculature, and evidence suggests that during hyperglycemia, reduced NO availability exists [65]. Hyperglycemia-induced superoxide generation contributes to the increased expression of NAD(P)H oxidase, which in turn generate more superoxide anion. Hyperglycemia also favors, through the activation of NF-κB an increased expression of iNOS, which may increase the generation of NO [56,66].
Superoxide anion interacts with nitric oxide, forming the strong cytotoxin peroxynitrite (ONOO−), which attacks various biomolecules, leading — among other processes —to the production of a modified amino acid, nitrotyrosine [67]. Although nitrotyrosine was initially considered a specific marker of peroxynitrite generation, other pathways can also induce tyrosine nitration. Thus, nitrotyrosine is now generally considered a collective index of reactive nitrogen species, rather than a specific indicator of peroxynitrite formation [68,69]. The possibility that diabetes is associated with increased nitrosative stress is supported by the recent detection of increased nitrotyrosine plasma levels in type 2 diabetic patients [8] and iNOS-dependent peroxynitrite production in diabetic platelets [15]. Nitrotyrosine formation is detected in the artery wall of monkeys during hyperglycemia [70] and in diabetic patients during an increase of postprandial hyperglycemia [10,11]. In a recent study we have demonstrated increased nitrotyrosine immunoreactivity in microvasculature of type 2 diabetic patients [17]. In the same study significant correlations were observed between nitrotyrosine immunostaining intensity and fasting blood glucose, HbA1c, intracellular adhesion molecule (ICAM), and vascular cellular adhesion molecule (VCAM).
The toxic actions of nitrotyrosine in the cardiovascular system are also highlighted by the evidence showing that there is increased apoptosis of endothelial cells, myocytes and fibroblasts in heart biopsies from diabetic patients [25], in hearts from streptozotocin-induced diabetic rats [26], and in working hearts from rats during hyperglycemia [28]. Importantly, the degree of cell death and/or dysfunction shows a correlation with levels of nitrotyrosine found in those cells. There is also evidence that nitrotyrosine can be directly harmful to endothelial cells [71]. In addition, high glucose-induced oxidative and nitrosative stress pathologically alters prostanoid profile in human endothelial cells [19,21].
Recent evidence indicates that there may be several phases to the pathogenesis of the endothelial injury induced by high glucose: the short-term effect appear to depend on a combined oxidative and nitrosative stress with peroxynitrite formation, whereas the long-term effect is related to reactive oxygen species generation; in both cases, protein kinase C ultimately mediates the vascular permeability changes [22].
Angiotensin II is a known factor in the pathogenesis of diabetic complications, perhaps most importantly, in nephropathy, cardiomyopathy and retinopathy. Recent studies indicate that the protective effects of angiotensin converting enzyme inhibitors or angiotensin receptor antagonists may go beyond the blood pressure lowering effects of these agents [72–74]. Furthermore, ACE inhibition in vivo reduces the apparent formation of peroxynitrite [35]. In this context it is noteworthy that angiotensin II can induce direct, pro-oxidative effects on the vascular endothelium. These effects are, at least in part, mediated by intraendothelial reactive species formation via a new family of NAD(P)H oxidase subunits, known as the non-phagocytic NAD(P)H oxidase proteins. Reactive oxidant species produced following angiotensin II-mediated stimulation of NAD(P)H oxidases can exert direct oxidative effects, but can also signal through pathways such as mitogen-activated protein kinases, tyrosine kinases and transcription factors, and lead to events such as inflammation, hypertrophy, remodeling and angiogenesis [54]. Recent work demonstrates that angiotensin II can also induce intraendothelial peroxynitrite formation [6,75–77], as well as PARP activation [76,77].
Diabetic cardiomyopathy is characterized by complex changes in the mechanical, biochemical, structural, and electrical properties of the heart, which may be responsible for the development of an early diastolic dysfunction and increased incidence of cardiac arrhythmias in diabetic patients. The mechanism of diastolic dysfunction remains unknown but it does not appear to be due to changes in blood pressure, microvascular complications or elevated circulating glycated hemoglobin levels [78–82]. There is circumstantial clinical and experimental evidence suggesting that increased sympathetic activity, activated cardiac renin-angiotensin system, myocardial ischemia/functional hypoxia, and elevated circulating levels of glucose result in oxidative and nitrosative stress in cardiovascular system of diabetic animals and humans. Oxidative stress associated with an impaired antioxidant defense status may play a critical role in subcellular remodeling, calcium-handling abnormalities, and subsequent diabetic cardiomyopathy [26,82,83].
Oxidative and nitrosative damage may be critical in the early onset of diabetic cardiomyopathy [18,25,26,28]. Even in simple model systems, e.g. placement of beating myocytes into culture medium containing elevated glucose, the pathophysiological alterations can be attenuated by antioxidants, NOS inhibitors, as well as by peroxynitrite neutralizing agents [84]. Consistently with the in vivo importance of this latter pathomechanism, significant nitrotyrosine formation was reported in cardiac myocytes from myocardial biopsy samples obtained from diabetic and diabetic hypertensive patients [25] and in a mouse model of STZ-induced diabetes [26]. Perfusion of isolated hearts with high glucose caused a significant upregulation of iNOS, increased the coronary perfusion pressure and both NO and superoxide generation, a condition favoring the production of peroxynitrite, accompanied by the formation of nitrotyrosine and cardiac cell apoptosis [28]. Fig. (1) shows increased NT formation in STZ-induced diabetic rat tissues.
Fig. 1
Fig. 1
Increased nitrotyrosine (NT) formation in diabetic tissues
As mentioned above there is circumstantial evidence that nitrosative stress and peroxynitrite formation importantly contribute to the pathogenesis of diabetic cardiomyopathy both in animals and humans. We have tested a novel metalloporphyrin peroxynitrite decomposition catalyst, FP15, in murine models of diabetic cardiovascular complications [18]. We hypothesized that neutralization of peroxynitrite with FP15 would ameliorate the development of cardiovascular dysfunction in a streptozotocin-induced murine model of diabetes. In order to ensure that the animals received the FP15 treatment at a time when islet cell destruction was already complete and hyperglycemia has stabilized the treatment was initiated six week after the injection of streptozotocin. Although FP15 did not affect blood glucose levels, it provided a marked protection against the loss of endothelium-dependent relaxant ability of the blood vessels (Fig. 2A) and improved the depression of both diastolic (Fig. 2B) and systolic function of the heart [18]. The mechanism by which FP15 protects diabetic hearts from dysfunction may involve protection against vascular and myocardial tyrosine nitration, PARP activation, lipid peroxidation, and multiple other mechanisms, as all these mechanisms have previously been linked to diabetic cardiomyopathy as well as to peroxynitrite-induced cardiac injury. Additional mechanisms of peroxynitrite-mediated diabetic cardiac dysfunction may include inhibition of myofibrillar creatine kinase [85] and of succinyl-CoA:3-oxoacid CoAtransferase [27] or activation of metalloproteinases [45,86].
Fig. 2
Fig. 2
Panel A. Reversal of diabetes-induced endothelial dysfunction by the porphyrinic peroxynitrite decomposition catalyst, FP15, in vascular rings from STZ-diabetic mice
There are many pathophysiological conditions of the heart that are associated with peroxynitrite formation, including acute myocardial infarction, chronic ischemic heart failure, doxorubicin-induced and diabetic cardiomyopathy [86–91]. It appears that peroxynitrite decomposition catalysts improve cardiac function and overall outcome in these models. For instance, FP15 reduced myocardial necrosis in our current rat model of acute myocardial infarction [86] as well as in a recent porcine study [87]. Furthermore, FP15 significantly improved cardiac function in a doxorubicin-induced model of heart failure [86]. These observations-coupled with the recently reported protective effect of FP15 against diabetic cardiomyopathy-support the concept that peroxynitrite is a major mediator of myocardial injury in various pathophysiological conditions, and its effective neutralization can be of significant therapeutic benefit.
Recent studies have suggested that increased oxidative and nitrosative stress is involved in the pathogenesis of diabetic microvascular injury in retinopathy nephropathy and neuropathy [33–46, 92,93] (Table 2, Fig. (1)).
Retinal endothelial cells maintained in high glucose had significant increased eNOS expression and activity as well as increased formation of superoxide anion and nitrotyrosine [40,41]. Each of these alterations was blocked by the NOS inhibitor, L-NAME, or the peroxynitrite scavenger, uric acid. Consistently with these observation there is increased oxidative and nitrosative stress in retinas of diabetic animals, which is attenuated by antioxidant treatment [39–41]. In addition increased peroxynitrite-mediated VEGF and urokinase plasminogen activator receptor expression was demonstrated and proposed to be responsible for the breakdown of the blood-retina barrier in diabetic animals [40,41].
Increased oxidative stress and nitrotyrosine formation have also been demonstrated both in kidneys of diabetic animals [34–36] and in biopsies from patients with diabetic nephropathy [33] suggesting pathogenetic role in the development of this complication.
Although hyperglycemia has been proven to cause peripheral nerve dysfunction in patients with diabetes, the biochemical mechanisms for this effect are poorly understood [94]. Recent studies in experimental animals have indicated that hyperglycemia stimulates the production of nitric oxide, which reacts with superoxide anion to form peroxynitrite, which is damaging the endothelium and perineurium [42–44,46,93]. In a recent murine study, sciatic motor nerve conduction velocity and hind-limb digital sensory conduction velocity were reduced in diabetic mice versus controls, and both indices were normalized by FP15, a peroxynitrite decomposition catalyst compound [95], which also ameliorated the accumulation of poly(ADP-ribose) accumulation in diabetic nerves [95].
It is noteworthy that in preclinical studies, administration of the aldose reductase inhibitors sorbinil or fidarestat to diabetic rats not only corrected diabetes-induced depletion of glutathione and ascorbate, downregulation of SOD activity and accumulation of lipid peroxidation products in the peripheral nerve, superoxide formation in vasa nervorum and of diabetes-associated retinal oxidative and nitrosative stress, but also inhibited poly(ADP-ribose) accumulation (a marker of PARP activation) in diabetic nerve and retina [96].
Peroxynitrite also damages DNA and thus triggers the activation of DNA repair systems. A DNA nick sensor enzyme, poly(ADP-ribose) polymerase-1 (PARP-1) also becomes activated upon sensing DNA breakage. Activated PARP-1 cleaves NAD+ into nicotinamide and ADP-ribose and polymerizes the latter on nuclear acceptor proteins. Peroxynitrite-induced overactivation of PARP consumes NAD+ and consequently ATP culminating in cell dysfunction, apoptosis or necrosis [6,97]. PARP-1 activation has recently been implicated in the pathogenesis of diabetes and diabetic complications [48] including cardiovascular dysfunction [16,37,98–103], nephropathy [104], neuropathy [99,105] and retinopathy [106].
CONCLUSIONS AND IMPLICATIONS
Taken together, multiple lines of evidence support the view that nitrosative stress and peroxyntrite-induced damage play a crucial role in multiple interrelated aspects of the pathogenesis of diabetes and its complications. Neutralization of reactive nitrogen species or inhibition of downstream pathways including PARP activation may emerge as a novel approach for the experimental therapy of diabetes, as well as for the prevention or reversal of its complications.
ABBREVIATIONS
AGEAdvanced glycation end product
AP-1Activator protein
DNADeoxyribonucleic acid
eNOSEndothelial nitric oxide synthase
ET-1Endothelin-1
ICAM-1Intracellular adhesion molecule
iNOSInducible nitric oxide synthase
NAD+Nicotinamide adenine dinucleotide
NTNitrotyrosine (an index of nitrosative stress and Peroxynitrite formation)
ONOO−Peroxynitrite
PARP/ PARSPoly(ADP-ribose) polymerase/synthase
PKCProtein kinase C
STZStreptozotocin
T2DMType 2 diabetes
T1DMType 1 diabetes
VCAM-1Vascular cellular adhesion molecule

References
1. Brownlee M. Nature. 2001;14:813–820. [PubMed]
2. Ceriello A. Diabetes Care. 2003;26:1589–1596. [PubMed]
3. Ruderman NB, Williamson JR, Brownlee M. FASEB J. 1992;6:2905–2914. [PubMed]
4. Hoeldtke RD. Clin Auton Res. 2003;13(6):406–421. [PubMed]
5. Nagai R, Unno Y, Hayashi MC, Masuda S, Hayase F, Kinae N, Horiuchi S. Diabetes. 2002;51(9):2833–2839. [PubMed]
6. Virag L, Szabo E, Gergely P, Szabo C. Toxicol Lett. 2003;140–141:113–124.
7. Matata BM, Galinanes M. J Thorac Cardiovasc Surg. 2000;120(1):1–11. [PubMed]
8. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L, Taboga C. Diabetologia. 2001;44:834–838. [PubMed]
9. Aydin A, Orhan H, Sayal A, Ozata M, Sahin G, Isimer A. Clin Biochem. 2001;34:65–70. [PubMed]
10. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Circulation. 2002;106(10):1211–1218. [PubMed]
11. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Diabetes Care. 2002;25:1439–1443. [PubMed]
12. Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G. J Clin Endocrinol Metab. 2003;88(4):1624–1628. [PubMed]
13. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Baylis C. Am J Hypertens. 2003;16(9 Pt 1):761–766. [PubMed]
14. Rabini RA, Vignini A, Salvolini E, Staffolani R, Martarelli D, Moretti N, Mazzanti L. Atherosclerosis. 2002;165(1):69–77. [PubMed]
15. Tannous M, Rabini RA, Vignini A, Moretti N, Fumelli P, Zielinski B, Mazzanti L, Mutus B. Diabetologia. 1999;42(5):539–544. [PubMed]
16. Garcia Soriano F, Virág L, Jagtap P, Szabó É, Mabley JG, Liaudet L, Marton A, Hoyt DG, Murthy KG, Salzman AL, Southan GJ, Szabo C. Nature Medicine. 2001;7:108–113.
17. Szabo C, Zanchi A, Komjati K, Pacher P, Krolewski AS, Quist WC, LoGerfo FW, Horton ES, Veves A. Circulation. 2002;106:2680–2686. [PubMed]
18. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, Soriano FG, Van Duzer JH, Williams W, Salzman AL, Groves JT. Mol Med. 2002;8:571–580. [PMC free article] [PubMed]
19. Zou MH, Shi C, Cohen RA. Diabetes. 2002;51:198–203. [PubMed]
20. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Diabetes. 2003;52(11):2795–2804. [PubMed]
21. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, Kouroedov A, Delli Gatti C, Joch H, Volpe M, Luscher TF. Circulation. 2003;107:1017–1023. [PubMed]
22. Pricci F, Leto G, Amadio L, Iacobini C, Cordone S, Catalano S, Zicari A, Sorcini M, Di Mario U, Pugliese G. Free Radic Biol Med. 2003;35(6):683–694. [PubMed]
23. Stadler K, Jenei V, von Bolcshazy G, Somogyi A, Jakus J. Free Radic Biol Med. 2003;35(10):1240–1251. [PubMed]
24. Brodsky SV, Gealekman O, Chen J, Zhang F, Togashi N, Crabtree M, Gross SS, Nasjletti A, Goligorsky MS. Circ Res. 2004;94(3):377–384. [PubMed]
25. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. Circ Res. 2000;87:1123–1132. [PubMed]
26. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, Anversa P. Diabetes. 2001;50(6):1414–1424. [PubMed]
27. Turko IV, Marcondes S, Murad F. Am J Physiol. 2001;281:2289–2294.
28. Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D. Diabetes. 2002;51:1076–1082. [PubMed]
29. Turko IV, Li L, Aulak KS, Stuehr DJ, Chang JY, Murad F. J Biol Chem. 2003;278(36):33972–33977. [PubMed]
30. Suarez-Pinzon WL, Szabo C, Rabinovitch A. Diabetes. 1997;46(5):907–911. [PubMed]
31. Lyall F, Gibson JL, Greer IA, Brockman DE, Eis AL, Myatt L. Diabetes Care. 1998;21(10):1753–1758. [PubMed]
32. Kossenjans W, Eis A, Sahay R, Brockman D, Myatt L. Am J Physiol Heart Circ Physiol. 2000;278(4):H1311–1319. [PubMed]
33. Thuraisingham RC, Nott CA, Dodd SM, Yaqoob MM. Kidney Int. 2000;57(5):1968– 1972. [PubMed]
34. Ishii N, Patel KP, Lane PH, Taylor T, Bian K, Murad F, Pollock JS, Carmines PK. J Am Soc Nephrol. 2001;12(8):1630–1639. [PubMed]
35. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrell LA, Jerums G, Osicka TM. Diabetes. 2002;51(11):3274–3282. [PubMed]
36. Onozato ML, Tojo A, Goto A, Fujita T, Wilcox CS. Kidney Int. 2002;61:186–194. [PubMed]
37. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M. J Clin Invest. 2003;112:1049–1057. [PMC free article] [PubMed]
38. Ellis EA, Guberski DL, Hutson B, Grant MB. Nitric Oxide. 2002;6:295–304. [PubMed]
39. Kowluru RA. Diabetes. 2003;52(3):818–823. [PubMed]
40. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Am J Pathol. 2003;162:1995–2004. [PubMed]
41. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. Invest Ophthalmol Vis Sci. 2003;44(7):3135–3143. [PubMed]
42. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Diabetes. 2001;50:1927–1937. [PubMed]
43. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Salvemini D, Yorek MA. Br J Pharmacol. 2001;134(1):21–29. [PubMed]
44. Hoeldtke RD, Bryner KD, McNeill DR, Hobbs GR, Riggs JE, Warehime SS, Christie I, Ganser G, Van Dyke K. Diabetes. 2002;51:2817–2825. [PubMed]
45. Bai P, Mabley JG, Liaudet L, Virag L, Szabo C, Pacher P. Oncology Reports. 2004;11(2):505–509. [PubMed]
46. Coppey LJ, Gellett JS, Davidson EP, Yorek MA. Free Radic Res. 2003;37(1):33–40. [PubMed]
47. Poladia DP, Bauer JA. Diabetes Metab Res Rev. 2003;19(4):313–319. [PubMed]
48. Pacher P, Szabo C. Antioxidants & Redox Signaling. 2005 in press.
49. Szabo C. Toxicol Lett. 2003;140–141:105–112.
50. Suarez-Pinzon WL, Mabley JG, Strynadka K, Power RF, Szabo C, Rabinovitch A. J Autoimmun. 2001;16(4):449–455. [PubMed]
51. Furchgott RF. Biosci Rep. 1999;19:235–251. [PubMed]
52. Caballero AE, Arora S, Saouaf R, Lim SC, Smakowski P, Park JY, King GL, LoGerfo FW, Horton ES, Veves A. Diabetes. 1999;48:1856–1862. [PubMed]
53. Cai H, Harrison DG. Circ Res. 2000;87:840–844. [PubMed]
54. Cai H, Griendling KK, Harrison DG. Trends Pharmacol Sci. 2003;24:471–478. [PubMed]
55. Calles–Escandon J, Cipolla M. Endocr Rev. 2001;22:36–52. [PubMed]
56. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. Circulation. 1997;96:25–28. [PubMed]
57. Cosentino F, Luscher TF. J Cardiovasc Pharmacol. 1998;32:S54–61. [PubMed]
58. Beckman JA. Circ Res. 2002;90:107–111. [PubMed]
59. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Br J Pharmacol. 2000;130:963–974. [PubMed]
60. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Circulation. 2002;105:1656–1662. [PubMed]
61. Guzik TJ, West NE, Black E, McDonald D, Ratnatunga C, Pillai R, Channon KM. Circ Res. 2000;86:85–90.
62. Kocsis E, Pacher P, Posa I, Nieszner E, Pogatsa G, Koltai MZ. Acta Physiol Scand. 2000;169(3):183–187. [PubMed]
63. Ungvari Z, Pacher P, Kecskemeti V, Papp G, Szollar L, Koller A. Cardiovasc Res. 1999;43(4):1018–1028. [PubMed]
64. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, Giardino I, Brownlee M. Nature. 2000;404:787–790. [PubMed]
65. Giugliano D, Ceriello A, Paolisso G. Diabetes Care. 1996;19:257–267. [PubMed]
66. Spitaler MM, Graier WF. Diabetologia. 2002;45:476–494. [PubMed]
67. Beckman JS, Koppenol WH. Am J Physiol. 1996;271:1424–1437.
68. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, et al. Nature. 1998;391:393–397. [PubMed]
69. Halliwell B. FEBS Lett. 1997;411:157–160. [PubMed]
70. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak N, Heinecke JW. J Clin Invest. 2001;107:853–860. [PMC free article] [PubMed]
71. Mihm MJ, Jing L, Bauer JA. J Cardiovasc Pharmacol. 2000;36(2):182–187. [PubMed]
72. Bell DS. Diabetes Care. 2003;26(8):2433–2441. [PubMed]
73. Bui BV, Armitage JA, Tolcos M, Cooper ME, Vingrys AJ. Diabetologia. 2003;46(3):401–408. [PubMed]
74. Lewis EJ, Lewis JB. Clin Exp Nephrol. 2003;7:1–8. [PubMed]
75. Mihm MJ, Wattanapitayakul SK, Piao SF, Hoyt DG, Bauer JA. Biochem Pharmacol. 2003;65:1189–1197. [PubMed]
76. Szabó C, Pacher P, Komjati K, Mabley JG, Benko R, Kollai M. FASEB J. 2003;17:A803.
77. Szabó C, Pacher P, Zsengellér Z, Vaslin A, Komjáti K, Benkö R, Mabley JG, Kollai M. Mol Med. 2004 in press.
78. Bell DS. Diabetes Care. 1995;18:708–714. [PubMed]
79. Fein FS. Diabetes Care. 1990;13:1169–1179. [PubMed]
80. Illan F, Valdes-Chavarri M, Tebar J, Garcia A, Pascual H, Soria F, Hernandez A, Vicente T. Clin Invest. 1992;70:403–410.
81. Joffe II, Travers KE, Perreault-Micale CL, Hampton T, Katz SE, Morgan JP, Douglas PS. J Am Coll Cardiol. 1999;34:2111–2119. [PubMed]
82. Regan TJ, Ahmed S, Haider B, Moschos C, Weisse A. N Engl J Med. 1994;91:776– 778.
83. Dhalla NS, Liu X, Panagia V, Takeda N. Cardiovasc Res. 1998;40:239–247. [PubMed]
84. Esberg LB, Ren J. Diabetologia. 2003;46(10):1419–1427. [PubMed]
85. Mihm MJ, Coyle CM, Schanbacher BL, Weinstein DM, Bauer JA. Cardiovasc Res. 2001;49:798–807. [PubMed]
86. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, Deb A, Szabo E, Ungvari Z, Wolin MS, Groves JT, Szabo C. Circulation. 2003;107:896–904. [PubMed]
87. Bianchi C, Wakiyama H, Faro R, Khan T, McCully JD, Levitsky S, Szabo C, Sellke FW. Ann Thorac Surg. 2002;74:1201–1207. [PubMed]
88. Mihm MJ, Bauer JA. Biochimie. 2002;84:1013–1019. [PubMed]
89. Pacher P, Liaudet L, Bai P, Virag L, Mabley J, Hasko G, Szabo C. J Pharmacol Exp Ther. 2002;300:862–687. [PubMed]
90. Pacher P, Liaudet L, Mabley J, Komjati K, Szabo C. J Am Coll Cardiol. 2002;40:1006–1016. [PubMed]
91. Weinstein DM, Mihm MJ, Bauer JA. J Pharmacol Exp Ther. 2000;294:396–401. [PubMed]
92. Du Y, Smith MA, Miller CM, Kern TS. J Neurochem. 2002;80:771–779. [PubMed]
93. Cheng C, Zochodne DW. Diabetes. 2003;52:2363–2371. [PubMed]
94. Obrosova IG. Curr Diab Rep. 2003;3:439–445. [PubMed]
95. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabó C. FASEB J. 2005 in press.
96. Obrosova IG, Pacher P, Szabo C, Zsengeller Z, Hirooka H, Stevens MJ, Yorek MA. Diabetes. 2005 in press.
97. Virag L, Szabo C. Pharmacol Rev. 2002;54:375–429. [PubMed]
98. Ceriello A, Piconi L, Quagliaro L, Ros RD, Marini C, Giugliano D, Szabo C. FASEB J. 2003;17:A260.
99. Obrosova IG, Li F, Abatan OI, Komjáti K, Pacher P, Szabo C, Stevens MJ. Diabetes. 2004;53:711–720. [PubMed]
100. Pacher P, Liaudet L, Soriano FG, Mabley JG, Szabó É, Szabó C. Diabetes. 2002;51:514–521. [PubMed]
101. Reusch JE. J Clin Invest. 2003;112(7):986–988. [PMC free article] [PubMed]
102. Soriano FG, Mabley JG, Pacher P, Liaudet L, Szabó C. Circ Res. 2001;89:684–691. [PubMed]
103. Soriano FG, Virag L, Szabo C. J Mol Med. 2001;79:437–448. [PubMed]
104. Minchenko AG, Stevens MJ, White L, Abatan OI, Komjáti K, Pacher P, Szabo C, Obrosova IG. FASEB J. 2003;17(11):1514–1516. [PubMed]
105. Li F, Szabo C, Pacher P, Southan GJ, Abatan OI, Charniauskaya T, Stevens MJ, Obrosova IG. Diabetologia. 2004;47:710–717. [PubMed]
106. Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, Szabo C. Int J Mol Med. 2004;14(1):55–64. [PubMed]